DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Vas Narasimhan - 2 atrasentan - 2 Narasimhan - 2 Kisqali - 2 Miranda Murray - 2 Kim Coghill - 2 Sonali Paul - 2 Novartis - 1
Top related locs:
United States Seattle Swiss IgAN
Top related orgs:
Novartis - 2 Chinook Therapeutics - 2 Sandoz - 2 Chinook - 2 Thomson - 2 Vera Therapeutics - 1 Seattle - 1 Swiss pharma - 1

Search resuls for: "atrasentan"


3 mentions found


☆ Novartis buys Chinook for $3.5 bln in race to treat rare kidney disease
  + stars: | 2023-06-12 | by ( Ludwig Burger | ) www.reuters.com   time to read: +3 min
June 12 (Reuters) - Novartis (NOVN.S) said it has agreed to acquire U.S. biotech firm Chinook Therapeutics (KDNY.O) for up to $3.5 billion to boost its late-stage drug development line-up, raising the stakes in the race for a rare kidney disease treatment. The other drug hopeful is iptacopan, which is being trialled against a number of rare genetic disorders, including IgAN and another kidney disease. IgAN is a progressive autoimmune disease that mostly affects young adults and which can lead to kidney failure that requires dialysis or organ transplantation. IgAN is the most common cause of kidney failure in Caucasian young adults, Novartis added. Additional reporting by Miranda Murray; Editing by Kim Coghill, Sonali Paul and Alexander SmithOur Standards: The Thomson Reuters Trust Principles.
Persons: Novartis, Vas Narasimhan, Narasimham, atrasentan, Narasimhan, Kisqali, Roche, Vera, Muddy Waters, Miranda Murray, Kim Coghill, Sonali Paul, Alexander Smith Organizations: Novartis, Chinook Therapeutics, Vera Therapeutics, Sandoz, Chinook, Thomson Locations: Seattle, United States
☆ Novartis to buy Chinook for up to $3.5 bln in boost to late-stage pipeline
  + stars: | 2023-06-12 | by ( Ludwig Burger | ) www.reuters.com   time to read: +2 min
June 12 (Reuters) - Novartis (NOVN.S) has agreed to acquire Seattle-based biotech firm Chinook Therapeutics (KDNY.O) for up to $3.5 billion to boost its late-stage drug development line-up with a new treatment for a rare severe kidney disease. Chinook is also working on zigakibart, another experimental IgAN treatment that is injected, and plans to start a Phase 3 trial in the third quarter of 2023. IgAN is a progressive autoimmune disease that mostly affects young adults and which can lead to dialysis or kidney transplantation. IgAN is the most common cause of kidney failure in Caucasian young adults, the company added. Additional reporting by Miranda Murray; Editing by Kim Coghill and Sonali PaulOur Standards: The Thomson Reuters Trust Principles.
Persons: Swiss drugmaker, Vas Narasimhan, atrasentan, Narasimhan, Kisqali, Soliris, Miranda Murray, Kim Coghill, Sonali Paul Organizations: Novartis, Seattle, Chinook Therapeutics, Chinook, Swiss pharma, Sandoz, Thomson Locations: Swiss, IgAN, United States
☆ Health-care stocks are looking good for 2023 and not just because the sector is a 'safe haven'
  + stars: | 2022-12-21 | by ( Christina Cheddar Berk | ) www.cnbc.com   time to read: +9 min
Investors looking for cover this year would have done well if they sought a safe haven in large-cap pharmaceutical stocks, a trend that is likely to continue into 2023. The Inflation Reduction Act provided some clarity around drug pricing that should help health-care stocks. The average price target, according to FactSet, is $62, or nearly 40% above the stock's closing price on Tuesday. Gene therapies in focus Investors will be closely watching the progress of several gene therapies, according to Phipps. "Yes, these are expensive therapies," Phipps said.
0 next >>
Total: 3